Microbiological Monitoring in Therapeutic Trials in Chronic Obstructive Pulmonary Disease
Background: Microbiological Monitoring in Therapeutic Trials in Chronic Obstructive Pulmonary Disease
Allinson and colleagues recently reported in the Journal that long-term treatment with doxycycline did not significantly reduce the exacerbation rate in patients with chronic obstructive pulmonary disease (COPD) (1). We would like to offer some comments to hopefully enrich the interpretation of these results.
Some comments to hopefully enrich the interpretation of these results
First, the characteristics of the study population are worth noting
All patients had frequent exacerbations (median of two exacerbations in the previous 1 yr), and 60% of them had chronic bronchitis.
This subgroup of patients with COPD frequently experience chronic bronchial infection (CBI) by potentially pathogenic microorganisms during times of clinical stability, including Haemophilus influenzae, Streptococcus pneumoniae, and Moraxella catarrhalis (2). CBI in these patients is associated with higher incidences of exacerbations and pneumonia (3), which are often sensitive to doxycycline (4). Unfortunately, Allinson and colleagues did not report microbiological sputum data, so the influence of CBI on the potential preventive effect of doxycycline on exacerbations could not be analyzed.
Second, it is of note that long-term doxycycline treatment was actually effective in preventing exacerbations in the subgroups of patients with more severe COPD
Even though the overall results were negative, it is of note that long-term doxycycline treatment was actually effective in preventing exacerbations in the subgroups of patients with more severe COPD (rate ratio, 0.36; 95% confidence interval, 0.15–0.85; P = 0.019) and/or less peripheral eosinophilia (rate ratio, 0.50; 95% confidence interval, 0.29–0.84; P = 0.01).
Previous studies have shown that the prevalence of CBI is higher in patients with more severe COPD and in those with lower blood eosinophil levels (5).
Thus, it is possible that the significant effects seen in patients with more severe COPD and/or lower peripheral eosinophil counts can be due to the long-term effects of doxycycline on CBI without ruling out an additional antiinflammatory effect of doxycycline, as pointed out by the authors.
Conclusions
In summary, we think this study highlights the need for careful microbiological monitoring (and, if possible, analysis of potential pulmonary microbiome changes, i.e., dysbiosis) in future interventional trials in patients with COPD.
Authors
Miguel Angel Martinez-Garcia and Alvar Agusti.
Read more details at
Noticias relacionadas
COPD in the 21st Century
COPD in the 21st Century: Alvar Agustì and Rosa Faner are part of this book, being authors of chapter 4. Scientists and clinicians across many countries have made great efforts to understand this important disease, and these have yielded positive results.
Coffee Talk: CADSET-explaining the lung function tracker tool
The latest episode of Coffee Talk sees co-chairs of the ERS Clinical Research Collaboration CADSET, Prof. Erik Melén and Prof. Rosa Faner, catch up to discuss the topic of the new lung function tracker tool.
Lung Tissue Multi-Layer Network Analysis Uncovers the Molecular Heterogeneity of COPD
Chronic Obstructive Pulmonary Disease (COPD) is a heterogeneous condition. We hypothesized that the unbiased integration of different COPD lung omics using a novel multi-layer approach may unravel mechanisms associated with clinical characteristics.
Artículos
COPD
- 759785·Richard Beasley et Al – Prevalence, Diagnostic Utility and Associated Characteristics of Bronchodilator Responsiveness
- 759788·Alvar Agustí, Rod Hughes, Eleni Rapsomaki, Barry Make, Ricardo Del Olmo, Alberto Papi, David Price, Laura Benton, Stefan Franzen, Jørgen Vestbo, Hana Mullerova – The many faces of COPD in real life: a longitudinal analysis of the NOVELTY cohort
- 759883·Alberto Papi, Rosa Faner, Ian Pavord, Federico Baraldi, Vanessa M McDonald, Mike Thomas, Marc Miravitlles, Nicholas Roche, Alvar Agustí. – From treatable traits to GETomics in airway disease: moving towards clinical practice
- 768799·Surya P Bhatt Richard Casaburi Alvar Agusti et Al. Chronic obstructive pulmonary disease: hiding in plain sight, a Statement from the COPD Foundation Medical and Scientific Advisory Committee
- 768885·Miguel Angel Martinez-García, Alvar Agustí. – Microbiological Monitoring in Therapeutic Trials in Chronic Obstructive Pulmonary Disease
Estudios
- 759689·Kilian Vellvé et Alt.- Pulmonary vascular reactivity in growth restricted fetuses using computational modelling and machine learning analysis of fetal Doppler waveforms.
- 769273· Singh D, Criner GJ, Agustí A et al. Benralizumab Prevents Recurrent Exacerbations in Patients with Chronic Obstructive Pulmonary Disease: A Post Hoc Analysis
- 769685·Nuria Olvera et Al.- Lung Tissue Multi-Layer Network Analysis Uncovers the Molecular Heterogeneity of COPD
- 769799·Alvar Agusti, Peter G. Gibson, Vanessa M. McDonald. Treatable Traits in Airway Disease: From Theory to Practice
- 778991·Mona Bafadhel, Rosa Faner, Camille Taillé, Richard E.K. Russell, Tobias Welte, Peter J. Barnes and Alvar Agustí. Inhaled corticosteroids for the treatment of COVID-19
Imagen obtenida en Canva Pro.
